Total Valuation
SpyGlass Pharma has a market cap or net worth of $952.60M. The enterprise value is $511.96M.
Market Cap$952.60M
Enterprise Value$511.96M
Share Statistics
SpyGlass Pharma has 33,447,980 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding33,447,980
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
SpyGlass Pharma’s return on equity (ROE) is 0.40 and return on invested capital (ROIC) is -38.64%.
Return on Equity (ROE)0.40
Return on Assets (ROA)-0.34
Return on Invested Capital (ROIC)-38.64%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee0.00
Profits Per Employee-524.59K
Employee Count76
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of SpyGlass Pharma is ―. SpyGlass Pharma’s PEG ratio is 0.00.
PE Ratio―
PS Ratio0.00
PB Ratio-8.52
Price to FCF-25.16
Price to Operating Cash Flow-20.46
PEG Ratio0.00
Income Statement
In the last 12 months, SpyGlass Pharma had revenue of 0.00 and earned -39.87M in profits. Earnings per share was -1.25.
Revenue0.00
Gross Profit-612.00K
Operating Income-41.45M
Pretax Income-39.87M
Net Income-39.87M
EBITDA-39.26M
Earnings Per Share (EPS)-1.25
Cash Flow
In the last 12 months, operating cash flow was -46.56M and capital expenditures -3.18M, giving a free cash flow of -49.74M billion.
Operating Cash Flow-46.56M
Free Cash Flow-49.74M
Free Cash Flow per Share-1.49
Dividends & Yields
SpyGlass Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.08
52-Week Price Change7.88%
50-Day Moving Average26.68
200-Day Moving Average―
Relative Strength Index (RSI)62.88
Average Volume (3m)123.47K
Important Dates
SpyGlass Pharma upcoming earnings date is Aug 6, 2026, After Close (Confirmed).
Last Earnings DateMay 14, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
SpyGlass Pharma as a current ratio of 12.67, with Debt / Equity ratio of 0.70%
Current Ratio12.67
Quick Ratio12.67
Debt to Market Cap0.00
Net Debt to EBITDA2.41
Interest Coverage Ratio0.00
Taxes
In the past 12 months, SpyGlass Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
SpyGlass Pharma EV to EBITDA ratio is -19.05, with an EV/FCF ratio of -22.33.
EV to Sales0.00
EV to EBITDA-19.05
EV to Free Cash Flow-22.33
EV to Operating Cash Flow-22.86
Balance Sheet
SpyGlass Pharma has $234.19M in cash and marketable securities with $1.63M in debt, giving a net cash position of $232.55M billion.
Cash & Marketable Securities$234.19M
Total Debt$1.63M
Net Cash$232.55M
Net Cash Per Share$6.95
Tangible Book Value Per Share-$3.10
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for SpyGlass Pharma is $39.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$39.33
Price Target Upside47.65% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast―